Loading clinical trials...
Loading clinical trials...
Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma
Conditions
Interventions
Sorafenib+Pazopanib
Pazopanib+Sorafenib
Locations
72
Austria
Medizinische Universität Innsbruck
Innsbruck, Austria
A. ö. Bezirkskrankenhaus Kufstein
Kufstein, Austria
AKH Linz GmbH
Linz, Austria
LKH Salzburg
Salzburg, Austria
Universitätsklinikum Aachen, Urologische Klinik
Aachen, Germany
Gesundheitszentrum St. Marien GmbH
Amberg, Germany
Start Date
May 1, 2012
Primary Completion Date
October 30, 2016
Last Updated
April 20, 2017
NCT07485114
NCT06391099
NCT05738694
NCT07227402
NCT06349642
NCT07300241
Lead Sponsor
Technical University of Munich
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions